Abbott (NYSE:ABT) reached an agreement with Dexcom (Nasdaq:DXCM) to settle all outstanding patent disputes between companies.
Abbott, a leader in diabetes tech with one of the biggest lines of continuous glucose monitors, announced this week that it's ...
GlobalData on MSN3mon
FDA hits Abbott FreeStyle Libre 3 recall with Class I tagThe US Food and Drug Administration (FDA) has tagged Abbott’s recent recall of its faulty FreeStyle Libre 3 sensors as Class ...
Meanwhile, the UK launch of Freestyle Libre 3 comes as rival real-time CGM player Dexcom received a European CE mark for its G7 device for people with diabetes aged two years and older.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback